Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

被引:27
作者
Fujimoto, Yukie [1 ]
Watanabe, Takahiro [2 ]
Hida, Akira I. [3 ]
Higuchi, Tomoko [1 ]
Miyagawa, Yoshimasa [1 ]
Ozawa, Hiromi [1 ]
Bun, Ayako [1 ]
Fukui, Reiko [1 ]
Sata, Atsushi [1 ]
Imamura, Michiko [1 ]
Hirota, Seiichi [2 ]
Miyoshi, Yasuo [1 ]
机构
[1] Hyogo Coll Med, Dept Surg, Div Breast & Endocrine Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Surg Pathol, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[3] Matsuyama Shimin Hosp, Dept Pathol, 2-6-5 Otemachi, Matsuyama, Ehime 7900067, Japan
关键词
Breast cancer; Tumor-infiltrating lymphocytes; Ki67; Prognosis; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; HIGHLIGHTS; CHEMOTHERAPY; SUBTYPES;
D O I
10.1007/s12282-019-00977-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2-subtype remains unclear. Methods We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low (< 10%), intermediate (10-50%), and high (> 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels. Results Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027). Conclusions In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 -subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 26 条
[1]   Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer [J].
Blok, Erik J. ;
Engels, Charla C. ;
Dekker-Ensink, Geeske ;
Kranenbarg, Elma Meershoek-Klein ;
Putter, Hein ;
Smit, Vincent T. H. B. M. ;
Liefers, Gerrit-Jan ;
Morden, James P. ;
Bliss, Judith M. ;
Coombes, R. Charles ;
Bartlett, John M. S. ;
Kroep, Judith R. ;
van de Velde, Cornelis J. H. ;
Kuppen, Peter J. K. .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) :65-74
[2]   Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+and foxp3+using double immunostaining with correlation to the pathobiological response of the patients [J].
Chan, Monica S. M. ;
Wang, Lin ;
Felizola, Saulo J. A. ;
Ueno, Takayuki ;
Toi, Masakazu ;
Loo, W. ;
Chow, Louis W. C. ;
Suzuki, Takashi ;
Sasano, Hironobu .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2012, 27 (04) :E295-E304
[3]   Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].
Coates, A. S. ;
Winer, E. P. ;
Goldhirsch, A. ;
Gelber, R. D. ;
Gnant, M. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546
[4]   Immune checkpoint inhibitors: recent progress and potential biomarkers [J].
Darvin, Pramod ;
Toor, Salman M. ;
Nair, Varun Sasidharan ;
Elkord, Eyad .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 :1-11
[5]   Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Darb-Esfahani, Silvia ;
Lederer, Bianca ;
Heppner, Barbara I. ;
Weber, Karsten E. ;
Budczies, Jan ;
Huober, Jens ;
Klauschen, Frederick ;
Furlanetto, Jenny ;
Schmitt, Wolfgang D. ;
Blohmer, Jens-Uwe ;
Karn, Thomas ;
Pfitzner, Berit M. ;
Kuemmel, Sherko ;
Engels, Knut ;
Schneeweiss, Andreas ;
Hartmann, Arndt ;
Noske, Aurelia ;
Fasching, Peter A. ;
Jackisch, Christian ;
van Mackelenbergh, Marion ;
Sinn, Peter ;
Schem, Christian ;
Hanusch, Claus ;
Untch, Michael ;
Loibl, Sibylle .
LANCET ONCOLOGY, 2018, 19 (01) :40-50
[6]   Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Brase, Jan C. ;
Sinn, Bruno V. ;
Gade, Stephan ;
Kronenwett, Ralf ;
Pfitzner, Berit M. ;
Salat, Christoph ;
Loi, Sherene ;
Schmitt, Wolfgang D. ;
Schem, Christian ;
Fisch, Karin ;
Darb-Esfahani, Silvia ;
Mehta, Keyur ;
Sotiriou, Christos ;
Wienert, Stephan ;
Klare, Peter ;
Andre, Fabrice ;
Klauschen, Frederick ;
Blohmer, Jens-Uwe ;
Krappmann, Kristin ;
Schmidt, Marcus ;
Tesch, Hans ;
Kuemmel, Sherko ;
Sinn, Peter ;
Jackisch, Christian ;
Dietel, Manfred ;
Reimer, Toralf ;
Untch, Michael ;
Loibl, Sibylle .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991
[7]   Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].
Denkert, Carsten ;
Loibl, Sibylle ;
Noske, Aurelia ;
Roller, Marc ;
Mueller, Berit Maria ;
Komor, Martina ;
Budczies, Jan ;
Darb-Esfahani, Silvia ;
Kronenwett, Ralf ;
Hanusch, Claus ;
von Toerne, Christian ;
Weichert, Wilko ;
Engels, Knut ;
Solbach, Christine ;
Schrader, Iris ;
Dietel, Manfred ;
von Minckwitz, Gunter .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113
[8]   Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance [J].
Dunbier, Anita K. ;
Ghazoui, Zara ;
Anderson, Helen ;
Salter, Janine ;
Nerurkar, Ashutosh ;
Osin, Peter ;
A'hern, Roger ;
Miller, William R. ;
Smith, Ian E. ;
Dowsett, Mitch .
CLINICAL CANCER RESEARCH, 2013, 19 (10) :2775-2786
[9]   Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [J].
Goldhirsch, A. ;
Wood, W. C. ;
Gelber, R. D. ;
Coates, A. S. ;
Thuerlimann, B. ;
Senn, H.-J. ;
Members, Panel .
ANNALS OF ONCOLOGY, 2007, 18 (07) :1133-1144
[10]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223